Journals | Policy | Permission

Journal of Clinical Medicine Research

Case Report

Volume 9, Number 1, January 2017, pages 74-78

Magnetic Resonance Spectroscopy and Single-Photon Emission Computed Tomography in the Evaluation of Cerebral Tumors: A Case Report

Magnetic resonance spectroscopy (MRS), firstly introduced for clinical use in 1990, was recognized as one of the most promising tools in detecting metabolic activity profiles that could help in non-invasive histological discrimination of brain tumors [1]. Since then and for the last decades, MRS combined with other magnetic resonance imaging (MRI) advanced techniques such as perfusion-weighted imaging (PWI) and diffusion-weighted imaging (DWI) has become a routine pre-surgical evaluation method of intracranial tumors [2-10]. In addition, MRS is popularized among scientists as a valuable diagnostic modality in several other pathological conditions such as hypoxia-ischemia in neonates, head trauma, epilepsy, leukodystrophies and metabolic diseases [11, 12].

The definition of tumor histology and grade is very important for the treatment strategizing. Despite its high performance, MRS solely or in combination with other advanced MRI techniques cannot resolve differential diagnostic dilemmas in some cases. A possible solution to this problem would be the supplemental use of other imaging modalities which could contribute significantly to the recognition of the tumor histopathological profile.

In this case report, we present an interesting case of a 66-year-old woman who had a supratentorial intracranial lesion with MRI characteristics similar to glioma. The combination of MRS and single-photon emission computed tomography (SPECT) with technetium-99m (Tc99m) led to the pre-operative diagnosis of a meningioma which was confirmed by the histopathological analysis of the tumor specimen.

A 66-year-old woman was admitted to our hospital for scheduled resection of a right parasagittal brain lesion. She had a history of epileptic seizures and anti-phospholipid syndrome related to a non-Hodgkin lymphoma in remission. The patient underwent brain MRI, ¹H-MRS and brain SPECT as part of a protocol which was based on the collaboration of the Departments of Medical Physics, Radiology and Neurosurgery aiming to study the combination of brain SPECT and MRI advanced techniques in the amelioration of brain tumor diagnosis. A 3-Tesla MRI scanner (GE, Healthcare, Signa^® HDx) was used. ¹H-MRS study was feasible through two different spectroscopy imaging protocols: proton brain exam (PROBE) single voxel (SV) and two-dimensional multivoxel (2D chemical shift imaging (CSI)) spectroscopy. The used sequence was point-resolved spectroscopy (PRESS) pulse with phase encoding gradients towards two directions, automatic and manual shimming and Gaussian water suppression. A single voxel with a volume less than 3.4 mL was cautiously obtained from the tumor area away from the tumor margins by applying measurements of 1,500/35 m/s (TR/TE) and using 128 signal acquisitions (Nacq). 2D CSI technique was applied to the measurements of 1,000/144 m/s (TR/TE) by using 16 × 16 phase encoding steps, with a thickness of 10 mm based on the patient’s intracranial topography. The duration of spectroscopy in both imaging protocols did not exceed the 4 - 5 min. Besides the tumor area, spectroscopic images were obtained also from the healthy brain tissue (Table 1). The localization of the desirable voxel area was retrospectively feasible through sagittal, axial and coronal images with T1-weighted FSE, T2-weighted FLAIR and T2-weighted imaging sequences. Contrast agent was used after the completion of the spectroscopy for the optimization of our surgical planning as these images were intergrated to our neuronavigation system.

Click to view

Table 1. The Ratios of NAA/Cr, Chol/Cr, and Chol/NAA According to the Performed 1H-MRS Study

The brain SPECT was performed 20 - 30 min after intravenous injection of 925MBq (25mCi) tracer activity. The Myoview^TM (General Electric Healthcare Ltd) was used for the preparation of the radiopharmaceutical which reconstituted with Tc-99m pertechnetate (99mTcO_4-) sterile solution in the Department of Nuclear Medicine. The processing and fusion of the obtained images was performed through the Xeleris Workstation (GE Healthcare).

According to conventional MRI examination, an enhancing right parasagittal brain lesion with significant edema was recognized. MRS examination raised the suspicion of glioma based on the metabolic profile at the center of the tumor which indicated high ratio of choline to N-acetylaspartate (Chol/NAA) (Figs. 1, 2). The SPECT examination indicated intense and homogenous uptake of the radiopharmaceutical, with notably high standardized uptake value (SUV), supporting the diagnosis of meningioma (Fig. 3). The patient underwent a right fronto-parietal craniotomy and her tumor was completely resected. The histopathological analysis of our specimen indicated the diagnosis of a meningioma grade I (Figs. 4, 5). The patient had an uneventful postoperative course and at her last follow-up she is tumor free.

Click for large image

Figure 1. MRI images in coronal (a), sagittal (b) and axial plane (c) demonstrating the area of the tumor where the voxel of the performed MRS study (d) was obtained.

Click for large image

Figure 2. 1H-MRS of the tumor area (left) showing the high Chol/NAA ratio in comparison to the normal MRS findings of the opposed normal brain tissue (right).

Click for large image

Figure 3. Axial images of the performed brain SPECT with technetium-99m (Tc99m) demonstrating high standardized uptake value (SUV).

Click for large image

Figure 4. The tumor cells form lobules some partly demarcated by thin collagenous septae (hematoxylin and eosin stain, original magnification × 10).

Click for large image

Figure 5. The tumor cells are uniform with oval nuclei with delicate chromatin that on occasion show central clearing or the formation of nuclear inclusions. Psammoma bodies are present (hematoxylin and eosin stain, original magnification × 40).

In vivo MRS is a well-known imaging MRI technique for the evaluation of tumor histology and grade. The accurate prediction of tumor type based on ¹H-MRS can reach 82.5% and according to the literature, this technique has 100% sensitivity and more that 90% specificity as a diagnostic method [13]. It is based on the detection of specific metabolites such as Chol, NAA, glutamate (Glu), glutamine (Gln), creatinine (Cr), myo-inositol, lactate and lipids [14-18]. NAA is synthesized in the neuronal mitochondria and transported into the cytosol, as well as along the axons of the neurons. It is present primarily in neuronal tissue, thus it is used as a marker of neuronal density and integrity. NAA reduction is observed in neuronal cell death usually seen in gliomas with grade II or more, glioblastomas, lymphomas, metastasis and gliomatosis, whereas in extra-axial tumors, such as meningiomas and schwannomas, NAA is usually absent [14, 16-18]. Chol is involved in cell membrane phospholipids’ synthesis-degradation and its levels are raised in increased cell membrane metabolism or abnormal neuronal cell increase [14, 16-18]. Cr/phosphocreatine is involved in cell energy capacity and decreases in any pathological condition associated with increased metabolic activity [14, 16-18]. Glx is the composite of Glu, Gln and gamma-aminobutyric acid (GABA) peaks. Glu is the most prevalent excitatory neurotransmitter in the brain and the precursor of the inhibitory neurotransmitter GABA [14, 16-18]. Myo-inositol is a specific glial marker as it can be found only in glial cells and subsequently in glial tumors where it is increased [14, 16-18]. Lactate is a marker of anaerobic glycolysis and its presence is detected in hypoxic and ischemic conditions, as well as in lesions with high rate of glycolysis and its elevation denotes higher tumor grade [14, 16-18]. At last, free lipids are observed in brain tissue necrosis and their presence is compatible with high grade malignant tumors, metastatic lesions, lymphomas and less with meningiomas [14, 16-18]. The metabolic profile of the brain lesion in our case according to the performed MRS study was characterized by high Chol/NAA ratio, a small increased concentration of lipids and lactate acid, high levels of myo-inositol and finally a small concentration of amino-acids. These findings were suggestive of a glioma.

Brain SPECT with Tc-99m was introduced in 1960s showing markedly the location of the tumor by demonstrating the disruption of the blood barrier in the pathological area [19]. Several radiopharmaceutical agents have been used until today such as Tc-99m diethylenetriaminepentaacetic acid (DTPA), Tc-99m glucoheptonate (Tc-99m GHA), thallium-201, Tc-99m tetrofosmin, and Tc-99m sestamibi [19]. The last decades this modality was repeatedly implemented for the detection of tumor recurrence or remnants in high grade gliomas and for brain tumors grading [19-23]. Furthermore, it was proved of significant value in the differentiation between tumor necrosis due to irradiation and recurrence in surgically treated high grade gliomas [24]. In our case, brain SPECT showed intense and homogenous uptake of the radiopharmaceutical with high SUV indicating the presence of a meningioma. According to the reported cases series in the literature, brain SPECT can help in the differentiation between gliomas and benign tumors and between typical and atypical meningiomas [22, 25].

In conclusion, ¹H-MRS with the supplemental information of the brain SPECT provided an accurate pre-surgical diagnosis in our case resolving a significant diagnostic dilemma. It seems that a multi-modality approach in the diagnosis of brain tumors would be of great benefit for the patients and also for the physicians who are involved in patient’s treatment planning.

Conflicts of Interest

None.

Financial Support

None.

1. Bottomley PA. Human in vivo NMR spectroscopy in diagnostic medicine: clinical tool or research probe? Radiology. 1989;170(1 Pt 1):1-15.
   doi pubmed
2. Guzman-De-Villoria JA, Mateos-Perez JM, Fernandez-Garcia P, Castro E, Desco M. Added value of advanced over conventional magnetic resonance imaging in grading gliomas and other primary brain tumors. Cancer Imaging. 2014;14:35.
   doi pubmed
3. Hollingworth W, Medina LS, Lenkinski RE, Shibata DK, Bernal B, Zurakowski D, Comstock B, et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol. 2006;27(7):1404-1411.
   pubmed
4. Julia-Sape M, Griffiths JR, Tate AR, Howe FA, Acosta D, Postma G, Underwood J, et al. Classification of brain tumours from MR spectra: the INTERPRET collaboration and its outcomes. NMR Biomed. 2015;28(12):1772-1787.
   doi pubmed
5. Moussazadeh N, Tsiouris AJ, Ramakrishna R. Advanced Imaging for Biopsy Guidance in Primary Brain Tumors. Cureus. 2016;8(2):e504.
   doi
6. Orphanidou-Vlachou E, Auer D, Brundler MA, Davies NP, Jaspan T, MacPherson L, Natarajan K, et al. (1)H magnetic resonance spectroscopy in the diagnosis of paediatric low grade brain tumours. Eur J Radiol. 2013;82(6):e295-301.
   doi pubmed
7. Rao PJ, Jyoti R, Mews PJ, Desmond P, Khurana VG. Preoperative magnetic resonance spectroscopy improves diagnostic accuracy in a series of neurosurgical dilemmas. Br J Neurosurg. 2013;27(5):646-653.
   doi pubmed
8. Rehman L, Rehman UL, Azmat SK, Hashim AS. Magnetic Resonance Spectroscopy: Novel Non-invasive Technique for Diagnosing Brain Tumors. J Coll Physicians Surg Pak. 2015;25(12):863-866.
   pubmed
9. Seeger A, Braun C, Skardelly M, Paulsen F, Schittenhelm J, Ernemann U, Bisdas S. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease. Acad Radiol. 2013;20(12):1557-1565.
   doi pubmed
10. Shiroishi MS, Panigrahy A, Moore KR, Nelson MD, Jr., Gilles FH, Gonzalez-Gomez I, Bluml S. Combined MRI and MRS improves pre-therapeutic diagnoses of pediatric brain tumors over MRI alone. Neuroradiology. 2015;57(9):951-956.
    doi pubmed
11. Oz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, Bolan PJ, et al. Clinical proton MR spectroscopy in central nervous system disorders. Radiology. 2014;270(3):658-679.
    doi pubmed
12. Ratai EM, Gilberto Gonzalez R. Clinical magnetic resonance spectroscopy of the central nervous system. Handb Clin Neurol. 2016;135:93-116.
    doi pubmed
13. Server A, Josefsen R, Kulle B, Maehlen J, Schellhorn T, Gadmar O, Kumar T, et al. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors. Acta Radiol. 2010;51(3):316-325.
    doi pubmed
14. Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol. 2009;64(1):12-21.
    doi pubmed
15. Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol. 2007;62(2):109-119.
    doi pubmed
16. Callot V, Galanaud D, Le Fur Y, Confort-Gouny S, Ranjeva JP, Cozzone PJ. (1)H MR spectroscopy of human brain tumours: a practical approach. Eur J Radiol. 2008;67(2):268-274.
    doi pubmed
17. Chaumeil MM, Lupo JM, Ronen SM. Magnetic Resonance (MR) Metabolic Imaging in Glioma. Brain Pathol. 2015;25(6):769-780.
    doi pubmed
18. Hall H, Cuellar-Baena S, Dahlberg C, In't Zandt R, Denisov V, Kirik D. Magnetic resonance spectroscopic methods for the assessment of metabolic functions in the diseased brain. Curr Top Behav Neurosci. 2012;11:169-198.
    doi pubmed
19. Alam SS, Junaid S, Ahmed SM. Evaluation of Technetium-99m glucoheptonate single photon emission computed tomography for brain tumor grading. Asian J Neurosurg. 2016;11(2):118-128.
    doi pubmed
20. Singh B, Kumar N, Sharma S, Watts A, Hazari PP, Rani N, Vyas S, et al. 99mTc-MDM Brain SPECT for the Detection of Recurrent/Remnant Glioma-Comparison With ceMRI and 18F-FLT PET Imaging: Initial Results. Clin Nucl Med. 2015;40(10):e475-479.
    doi pubmed
21. Alexiou GA, Fotopoulos AD, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Tsiouris S. Evaluation of brain tumor recurrence by (99m)Tc-tetrofosmin SPECT: a prospective pilot study. Ann Nucl Med. 2007;21(5):293-298.
    doi pubmed
22. Fotopoulos AD, Kyritsis AP, Tsiouris S, Al-Boucharali J, Papadopoulos A, Voulgaris S, Alexiou GA. Characterization of intracranial space-occupying lesions by (9)(9)(m)Tc-Tetrofosmin SPECT. J Neurooncol. 2011;101(1):83-89.
    doi pubmed
23. Santra A, Kumar R, Sharma P. Use of 99m-technetium-glucoheptonate as a tracer for brain tumor imaging: An overview of its strengths and pitfalls. Indian J Nucl Med. 2015;30(1):1-8.
    doi pubmed
24. Zhang H, Ma L, Wu C, Xu BN. Performance of SPECT in the differential diagnosis of glioma recurrence from radiation necrosis. J Clin Neurosci. 2015;22(2):229-237.
    doi pubmed
25. Fotopoulos AD, Alexiou GA, Goussia A, Papadopoulos A, Kyritsis AP, Polyzoidis KS, Voulgaris S, et al. (99m)Tc-Tetrofosmin brain SPECT in the assessment of meningiomas-correlation with histological grade and proliferation index. J Neurooncol. 2008;89(2):225-230.
    doi pubmed

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal of Clinical Medicine Research is published by Elmer Press Inc.